Joshua D. Duncan
Hepatitis C virus vaccine: Challenges and prospects
Duncan, Joshua D.; Urbanowicz, Richard A.; Tarr, Alexander W.; Ball, Jonathan K.
Richard A. Urbanowicz
Alexander W. Tarr
Jonathan K. Ball
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated.
|Journal Article Type||Review|
|Publication Date||Mar 1, 2020|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Duncan, J. D., Urbanowicz, R. A., Tarr, A. W., & Ball, J. K. (2020). Hepatitis C virus vaccine: Challenges and prospects. Vaccines, 8(1), https://doi.org/10.3390/vaccines8010090|
|Keywords||hepatitis C virus; vaccines; neutralising antibodies; animal models; immune responses|
You might also like
Cloning and analysis of authentic patient-derived HCV E1/E2 glycoproteins